Abo Bibliothek: Guest
Digitales Portal Digitale Bibliothek eBooks Zeitschriften Referenzen und Berichte Forschungssammlungen
Critical Reviews™ in Immunology
Impact-faktor: 1.404 5-jähriger Impact-Faktor: 3.347 SJR: 0.706 SNIP: 0.55 CiteScore™: 2.19

ISSN Druckformat: 1040-8401
ISSN Online: 2162-6472

Volumes:
Volumen 40, 2020 Volumen 39, 2019 Volumen 38, 2018 Volumen 37, 2017 Volumen 36, 2016 Volumen 35, 2015 Volumen 34, 2014 Volumen 33, 2013 Volumen 32, 2012 Volumen 31, 2011 Volumen 30, 2010 Volumen 29, 2009 Volumen 28, 2008 Volumen 27, 2007 Volumen 26, 2006 Volumen 25, 2005 Volumen 24, 2004 Volumen 23, 2003 Volumen 22, 2002 Volumen 21, 2001 Volumen 20, 2000 Volumen 19, 1999 Volumen 18, 1998 Volumen 17, 1997 Volumen 16, 1996 Volumen 15, 1995 Volumen 14, 1994

Critical Reviews™ in Immunology

DOI: 10.1615/CritRevImmunol.v18.i1-2.120
pages 109-119

Dendritic Cell-Based Immunotherapy of Prostate Cancer

M. L. Salgaller
Pacific Northwest Cancer Foundation and Northwest Hospital, 120 Northgate Plaza, Suite 205, Seattle, WA 98125;Northwest Biotherapeutics, LLC, 120 Northgate Plaza, Suite 219, Seattle, WA 98125
B. A. Tjoa
Pacific Northwest Cancer Foundation and Northwest Hospital, 120 Northgate Plaza, Suite 205, Seattle, WA 98125
P. A. Lodge
Pacific Northwest Cancer Foundation and Northwest Hospital, 120 Northgate Plaza, Suite 205, Seattle, WA 98125;Northwest Biotherapeutics, LLC, 120 Northgate Plaza, Suite 219, Seattle, WA 98125
H. Ragde
Pacific Northwest Cancer Foundation and Northwest Hospital, 120 Northgate Plaza, Suite 205, Seattle, WA 98125
G. Kenny
Pacific Northwest Cancer Foundation and Northwest Hospital, 120 Northgate Plaza, Suite 205, Seattle, WA 98125
A. Boynton
Pacific Northwest Cancer Foundation and Northwest Hospital, 120 Northgate Plaza, Suite 205, Seattle, WA 98125;Northwest Biotherapeutics, LLC, 120 Northgate Plaza, Suite 219, Seattle, WA 98125
G. P. Murphy
Pacific Northwest Cancer Foundation and Northwest Hospital, 120 Northgate Plaza, Suite 205, Seattle, WA 98125

ABSTRAKT

The immunotherapy of cancer, based on eliciting or enhancing the body’s own capacity to mount an effective antitumor response, has produced encouraging early results in the areas of melanoma and renal-cell carcinoma. Such treatments utilizing dendritic cells (DC), immune cells that are excellent antigen presenters, are especially promising. We performed a phase I clinical trial assessing the administration of autologous DC pulsed with HLA-A0201 -specific prostate-specific membrane antigen (PSMA) for the treatment of 51 men with hormone-refractory prostate cancer. Participants were divided into five groups receiving four or five infusions of peptides alone (PSM-P1 or PSM-P2; group 1 and 2, respectively), autologous DC (group 3), or DC pulsed with PSM-P1 or P2 (group 4 and 5, respectively). No significant toxicity was observed. Immune reactivity against PSM-P2 was detected in HLA-A2+ patients infused with DC pulsed with PSM-P1 or -P2 (group 4 and 5). An average decrease in PSA was observed only in group 5. Seven partial responders were identified based on NPCP criteria + PSA. The excellent tolerance of this treatment approach, as well as the enhanced cellular responses, decreased PSA levels, and partial clinical responses in some patients suggests that it holds great potential in prostate cancer therapy.


Articles with similar content:

Immunotherapy of Colon Cancer Using Chimeric mAb 31.1
Critical Reviews™ in Immunology, Vol.18, 1998, issue 1-2
Tommy Wang, Myron Arlen, Al Tsang
A Randomized, Placebo-Controlled, Multicenter Study of Ganoderma lucidum (W.Curt.:Fr.) Lloyd (Aphyllophoromycetideae) Polysaccharides (Ganopoly®) in Patients with Advanced Lung Cancer
International Journal of Medicinal Mushrooms, Vol.5, 2003, issue 4
Guoliang Chen, Jingxian Ye, Yihuai Gao, Shufeng Zhou, Xihu Dai
A Phase I/II Study of a Ganoderma lucidum (Curt.: Fr.) P. Karst. Extract (Ganopofy) in Patients with Advanced Cancer
International Journal of Medicinal Mushrooms, Vol.4, 2002, issue 3
Guoliang Chen, Jingxian Ye, Yihuai Gao, Shufeng Zhou, Xihu Dai
DETANONOate Is a Potent Chemo\ Radio-Sensitizing Agent in Colon and Colorectal Cancers as Assessed in In Vitro and In Vivo Established Tumor Xenografts
Forum on Immunopathological Diseases and Therapeutics, Vol.1, 2010, issue 4
Xiaohuan Gao, Sergio Huerta, Benjamin Bonavida
Immunotherapy for Triple-Negative Breast Cancer: Latest Research and Clinical Prospects
Critical Reviews™ in Immunology, Vol.39, 2019, issue 3
Farwah Jameel, Muhammad Irfan, Rida Fatima Ahmed